Highlights
- Prescient intends to raise AU$8.0 million via a Share Purchase Plan (SPP)
- Funds from the SPP will be used to develop the company’s pipeline of innovative cancer therapies and for general working capital.
- New fully paid ordinary shares will be distributed at $0.175 apiece.
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) announces a Share Purchase Plan (SPP) to raise AU$8.0 million.
Funds raised from the SPP will be used for the following:
- Clinical development of PTX-100 and PTX-200 targeted therapies
- Progressing its innovative cell therapies, OmniCAR and CellPryme-M, towards and into first-inhuman clinical studies
- General working capital and expenses of the offer
Prescient Advancing New Cancer Therapies with A Leading Team of Global Cancer Specialists
*Eligible shareholders - Registered shareholders as at 5:00pm (AEST) on Tuesday 23rd August 2022 (Record Date).
Indicative timetable of key dates for the SPP
Payment deadline: 5pm (AEST) on Wednesday, 28 September 2022.
Commenting on the SPP, the company’s CEO & Managing Director, Steven Yatomi-Clarke said that Prescient is seeking to maintain the momentum and position in the oncology space gained by the company during the last few years. He further added that the company is working to develop a diverse and groundbreaking pipeline of personalised therapies for cancer.
For more on SPP
Shareholders can find more information on Prescient’s SPP by clicking here.
To know more about Prescient Therapeutics Limited, click here. Also, to stay updated with PTX company activities and announcements, please update your details on their investor centre.
.